NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
PHARMACEUTICAL PREPARATIONS
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is listed on Nasdaq, where it has traded since November 23, 2022.
- Listed On
- Nasdaq
- Listed Since
- November 23, 2022
- Employees
- 100
- Market Cap
- $2.5B
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 191 institutions reported holding NAMS, with 122.0 million shares worth $4.1 billion in aggregate. The largest reported holder was Frazier Life Sciences Management,, with 18.1 million shares worth $613.0 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Frazier Life Sciences Management, | 18,088,902 | $613M | Added 6.76% |
| Capital Group | 13,954,052 | $473M | Added 11.19% |
| FMR | 10,339,663 | $350M | Added 17.95% |
| RA Capital Management, | 9,550,191 | $324M | Unchanged |
| Fcpm III Services B.V | 8,490,353 | $288M | Reduced 7.7% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is NAMS?
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is listed on Nasdaq, where it has traded since November 23, 2022.
Who are the largest institutional holders of NAMS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NAMS were Frazier Life Sciences Management,, Capital Group and FMR.
How many institutions own NAMS?
191 institutions reported a position in NAMS for the quarter ended June 30, 2026, worth $4.1 billion in total.
Did institutions buy or sell NAMS last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for NAMS.
Every reported institutional holder, plus insider and congressional trades in NAMS, on SentiSense.